The HYPOSENS consortium is delighted to release the project video. In less than three minutes, you will understand how the project developed a new system for better detection of breast cancer metastasis.
Brief Summary
Our breakthrough research focuses on the development, pre-clinical and clinical validation, and industrial demonstration of a unique all-optical cancer prognostic system. This system will detect the presence of cancer cells in the breast lymph nodes and characterize them, correlating with metastasis presence and poor prognosis.
The HypoSens imaging system is strategically designed to offer a minimally invasive alternative to the SLNB (Sentinel Lymph Node Biopsy) process. With an approximate cost of €60,000 per device unit and an additional €5,000 per patient, the device presents an affordable, accurate, and easy-to-use prognostic solution for clinicians. Once validated, it will enable more accurate, fast diagnoses and personalized treatment options.
Objectives
- Low-cost, compact, and easy-to-use device that accurately detects and measures luminescent signals through light scattering in body tissue.
- Break boundaries in specificity to target breast cancer tumors in SLN with specificity > 99% for micrometastases (0.2 mm).
- Achieve high resolution and sensitivity > 95% for in vivo, minimally invasive diagnosis in real time.
- Accurate measurement of dynamic cellular activity at the molecular level without interfering with intracellular processes, allowing long-term observation and improved diagnostic outcomes.
- Ensure the device design matches practical, social, economic, and regulatory needs.
